Evaluation of [18F]fluoroxanomeline {5-{4-[(6-[18F]fluorohexyl)oxy]-1,2,5-thiadiazol-3-yl}-1-methyl-1,2,3,6-tetrahydropyridine} in muscarinic knockout mice

Nuclear Medicine and Biology

Volumn 34, Issue 2, 2007, Pages 141-152

  Kiesewetter, Dale O ^a   Jagoda, Elaine M ^a   Shimoji, Kazuaki ^b   Ma, Ying ^a   Eckelman, William C ^b,c  

^a NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Molecular Tracer LLC   (United States)

Author keywords

Alzheimer's disease; Autoradiography; Muscarinic receptor; PET tracer

Indexed keywords

FLUORINE DERIVATIVE; FLUOROXANOMELINE; FLUOROXANOMELINE F 18; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR; PYRIDINE DERIVATIVE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; XANOMELINE; DIAGNOSTIC AGENT; MUSCARINIC RECEPTOR; RADIOPHARMACEUTICAL AGENT; THIADIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING KINETICS; BRAIN REGION; BRAIN STEM; CEREBELLUM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; FRONTAL CORTEX; HIPPOCAMPUS; INFERIOR COLLICULUS; KNOCKOUT MOUSE; MALE; MOUSE; NEUROIMAGING; NONHUMAN; RADIOCHEMISTRY; STATISTICAL SIGNIFICANCE; SUPERIOR COLLICULUS; TISSUE DISTRIBUTION; TISSUE SECTION; WILD TYPE; ANIMAL; ANTIBODY SPECIFICITY; BRAIN; EVALUATION; GENETICS; LIVER CELL; METABOLIC CLEARANCE RATE; METABOLISM; MOUSE MUTANT; RAT; SCINTISCANNING;

ANIMALS; BRAIN; HEPATOCYTES; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, KNOCKOUT; ORGAN SPECIFICITY; RADIOPHARMACEUTICALS; RATS; RECEPTORS, MUSCARINIC; THIADIAZOLES; TISSUE DISTRIBUTION;

EID: 33846899648     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.11.002     Document Type: Article

References (55)

1. Coyle J.T., Price D.L., and DeLong M.R. Alzheimer's disease - a disorder of cortical cholinergic innervation. Science 219 (1983) 1184-1190
2. Aubert I., Araujo D.M., Cecyre D., Robitaille Y., Gauthier S., and Quirion R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 58 (1992) 529-541
3. Quirion R., Aubert I., Lapchak P.A., Schaum R.P., Teolis S., Gauthier S., et al. Muscarinic receptor subtypes in human neurodegenerative disorders; focus on Alzheimer's disease. Trends Pharmacol Sci (1989) 80-84
4. Mulugeta E., Karlsson E., Islam A., Kalaria R., Mangat H., Winblad B., et al. Loss of muscarinic M-4 receptors in hippocampus of Alzheimer patients. Brain Res 960 (2003) 259-262
5. Flynn D.D., Ferrari-DiLeo G., Mash D.C., and Levey A.I. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 64 (1995) 1888-1891
6. Ferrari-DiLeo G., Mash D.C., and Flynn D.D. Attenuation of muscarinic receptor-G-protein interaction in Alzheimer-disease. Mol Chem Neuropathol 24 (1995) 69-91
7. Broadley K.J., and Kelley D.R. Muscarinic receptor agonists and antagonists. Molecules 6 (2001) 142-193
8. Sauerberg P., Olesen P.H., Nielsen S., Treppendahl S., Sheardown M.J., Honore T., et al. Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazoyl)-1,2,5,6-tetrahydro-1-methylpyridines. J Med Chem 35 (1992) 2274-2283
9. Scapecchi S., Matucci R., Bellucci C., Buccioni M., Dei S., Guandalini L., et al. Highly chiral muscarinic ligands: the discovery of (2S,2′R,3′S,5′R)-1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine 3-sulfoxide methyl iodide, a potent, functionally selective, M-2 partial agonist. J Med Chem 49 (2006) 1925-1931
10. Coimbra A., Williams D.S., and Hostetler E.D. The role of MRI and PET/SPECT in Alzheimer's disease. Curr Top Med Chem 6 (2006) 629-647
11. Maziere M. Cholinergic neurotransmission studied in vivo using positron emission tomography or single photon emission computerized tomography. Pharmacol Ther 66 (1995) 83-101
12. Kuhl D.E., Koeppe R.A., Minoshima S., Snyder S.E., Ficaro E.P., Foster N.L., et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 52 (1999) 691-699
13. Gibson R.E., Eckelman W.C., Reba R.C., Jagoda E.M., Rzeszotarski W.J., Grissom M., et al. Receptor-selective localization in pancreas. Int J Nucl Med Biol 12 (1985) 29-32
14. Gibson R.E., Schneidau T.A., Cohen V.I., Sood V., Ruch J., Melograna J., et al. In vitro and in vivo characteristics of [iodine-125] 3-(R)-quinuclidinyl (S)-4-iodobenzilate. J Nucl Med 30 (1989) 1079-1087
15. Tsukada H., Takahashi R., Miura S., Nishiyama S., Kakiuchi T., Ohba H., et al. Evaluation of novel PET ligands (+)N-[C-11]methyl-3-piperidyl benzilate ([C-11](+)3-MPB) and its stereoisomer [C-11](-)3-MPB for muscarinic cholinergic receptors in the conscious monkey brain: a PET study in comparison with [C-11]4-MPB. Synapse 39 (2001) 182-192
16. Nishiyama S., Tsukada H., Sato K., Kakiuchi T., Ohba H., Harada N., et al. Evaluation of PET ligands (+)N-[C-11]ethyl-3-piperidyl benzilate and (+)N-[C-11]propyl-3-piperidyl benzilate for muscarinic cholinergic receptors: a PET study with microdialysis in comparison with (+)N-[C-11]methyl-3-piperidyl benzilate in the conscious monkey brain. Synapse 40 (2001) 159-169
17. Boulay S.F., Sood V.K., Rayeq M.R., Zeeberg B.R., and Eckelman W.C. Autographic evidence that R-3-quinuclidinyl-S-4-fluoromethylbenzilate ((R,S)-FMeQNB) displays in vivo selectivity for muscarinic m2 subtype. Nucl Med Biol 23 (1996) 889-896
18. 123I-QNB, a SPECT imaging agent for cerebral muscarinic acetylcholine receptors in vivo. J Labelled Compd Radiopharm 31 (1992) 45-60
19. Raedler T.J., Knable M.B., Jones D.W., Urbina R.A., Egan M.F., and Weinberger D.R. Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology 28 (2003) 1531-1537
20. Kemp P.M., Holmes C., Hoffmann S., Wilkinson S., Zivanovic M., Thom J., et al. A randomised placebo controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer's disease. J Neurol Neurosurg Psychiatry 74 (2003) 1567-1570
21. McPherson D.W., Greenbaum M., Luo H., Beets A.L., and Knapp F.F. Evaluation of Z-(R,R)-IQNP for the potential imaging of m2 mAChR rich regions of the brain and heart. Life Sci 66 (2000) 885-896
22. Nobuhara K., Farde L., Halldin C., Karlsson P., Swahn C.G., Olsson H., et al. SPET imaging of central muscarinic acetylcholine receptors with iodine-123 labelled E-IQNP and Z-IQNP. Eur J Nucl Med 28 (2001) 13-24
23. Inch T.D., Green D.M., and Thompson P.B.J. The central and peripheral activities of anti-acetylcholine drugs. Some concepts of practical relevance. J Pharm Pharmacol 25 (1973) 359-370
24. Kiesewetter D.O., Lee J., Lang L., Park S.G., Paik C.H., and Eckelman W.C. Preparation of 18F-labeled muscarinic agonist with M2 selectivity. J Med Chem 38 (1995) 5-8
25. Podruchny T.A., Connolly C., Bokde A., Herscovitch P., Eckelman W.C., Kiesewetter D.O., et al. In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse 48 (2003) 39-44
26. Cohen R.M., Podruchny T.A., Bokde A.L.W., Carson R.E., Herscovitch P., Kiesewetter D.O., et al. Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-epsilon 4 allele. Synapse 49 (2003) 150-156
27. Bymaster F.P., McKinzie D.L., Felder C.C., and Wess J. Use of M-1-M-5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res 28 (2003) 437-442
28. Jagoda E.M., Kiesewetter D.O., Shimoji K., Ravasi L., Yamada M., Gomeza J., et al. Regional brain uptake of the muscarinic ligand, [F-18]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice. Neuropharmacology 44 (2003) 653-661
29. Kenakin T. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 24 (2003) 346-354
30. Korczyn A.D. Muscarinic M1 agonists in the treatment of Alzheimer's disease. Expert Opin Investig Drugs 9 (2000) 2259-2267
31. Bymaster F.P., Whitesitt C.A., Shannon H.E., DeLapp N., Ward J.S., Calligaro D.O., et al. A selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Dev Res 40 (1997) 158-170
32. Mirza N.R., Peters D., and Sparks R.G. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev 9 (2003) 159-186
33. Farde L., Suhara T., Halldin C., Nyback H., Nakashima Y., Swahn C.-G., et al. PET study of the M1-agonist [11C]xanomeline and [11C]butylthioTZTP in monkey and man. Dementia 7 (1996) 187-195
34. Gomeza J., Shannon H., Kostenis E., Felder C., Zhang L., Brodkin J., et al. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A 96 (1999) 1692-1697
35. Gomeza J., Zhang L., Kostenis E., Felder C., Bymaster F., Brodkin J., et al. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M-4 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A 96 (1999) 10483-10488
36. Miyakawa T., Yamada M., Duttaroy A., and Wess J. Hyperactivity and intact hippocampus-dependent learning in mice lacking the M-1 muscarinic acetylcholine receptor. J Neurosci 21 (2001) 5239-5250
37. Yamada M., Miyakawa T., Duttaroy A., Yamanaka A., Moriguchi T., Makita R., et al. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 410 (2001) 207-212
38. Fisahn A., Yamada M., Duttaroy A., Gan J.W., Deng C.X., McBain C.J., et al. Muscarinic induction of hippocampal gamma oscillations requires coupling of the M1 receptor to two mixed cation currents. Neuron 33 (2002) 615-624
39. Ma Y., Kiesewetter D.O., Jagoda E.M., Huang B.X., and Eckelman W.C. Identification of metabolites of fluorine-18-labeled M2 muscarinic receptor agonist, 3-(3-[(3-fluoropropyl)thio]-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine, produced by human and rat hepatocytes. J Chromatogr B - Analyt Technol Biomed Life Sci 766 (2002) 319-329
40. Huang Y.S., Hammond P.S., Wu L., and Mach R.H. Synthesis and structure-activity relationships of N-(1-benzylpiperidin-4-yl)arylacetamide analogues as potent sigma(1) receptor ligands. J Med Chem 44 (2001) 4404-4415
41. Gillespie TA, Lindsay TJ, Cornpropst D, Bonate PL, Skaggs TG, DeLong AF, Shipley LA. Analysis of xanomeline, a potential drug for Alzheimer's disease, by electrospray ionization tandem mass spectrometry. ACS. SYMP. Ser. Biochemical and Biotechnological Applications of Electrospray Ionization Mass Spectrometry, 619(1996);315-329.
42. Jeppesen L., Olesen P.H., Hansen L., Sheardown M.J., Thomsen C., Rasmussen T., et al. 1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.0(2,6)]heptanes as new potent muscarinic M-1 agonists: structure-activity relationship for 3-aryl-2-propyn-1-yloxy and 3-aryl-2-propyn-1-ylthio derivatives. J Med Chem 42 (1999) 1999-2006
43. Halldin C., Muller L., Foged C., Sauerberg P., Karlsson P., Swahn C.G., et al. Preparation of 3 C-11 labeled novel functional M1 selective muscarinic agonists. J Nucl Med 34 (1993) 7
44. Schwarz R.D., Davis R.E., Jaen J.C., Spencer C.J., Tecle H., and Thomas A.J. Characterization of muscarinic agonists in recombinant cell lines. Life Sci 52 (1993) 465-472
45. Saunders J. Ligand binding model for G-protein-linked receptors: an update. Drug Des Discov 9 (1993) 213-220
46. Dei S., Angeli P., Bellucci C., Buccioni M., Gualtieri F., Marucci G., et al. Muscarinic subtype affinity and functional activity profile of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)pyrrolidine and 1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine derivatives. Biochem Pharmacol 69 (2005) 1637-1645
47. Budriesi R., Cacciaguerra S., Di Toro R., Bolognesi M.L., Chiarini A., Minarini A., et al. Analysis of the muscarinic receptor subtype mediating inhibition of the neurogenic contractions in rabbit isolated vas deferens by a series of polymethylene tetra-amines. Br J Pharmacol 132 (2001) 1009-1016
48. Eglen R.M., Choppin A., and Watson N. Therapeutic, opportunities from muscarinic receptor research. Trends Pharmacol Sci 22 (2001) 409-414
49. Jagoda E.M., Kiesewetter D.O., Shimoji K., Ravasi L., Yamada M., Gomeza J., et al. Regional brain uptake of the muscarinic ligand, [F-18]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice. Neuropharmacology 44 (2003) 653-661
50. Gitler M.S., Cohen V.I., de la Cruz R., Boulay S.F., Jin B., Zeeberg B.R., et al. A novel muscarinic receptor ligand which penetrates the blood brain barrier and displays in vivo selectivity for the m2 subtype. Life Sci 53 (1993) 1743-1751
51. Watson J., Brough S., Coldwell M.C., Gager T., Ho M., Hunter A.J., et al. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. Br J Pharmacol 125 (1998) 1413-1420
52. Slutsky I., Wess J., Gomeza J., Dudel J., Parnas I., and Parnas H. Use of knockout mice reveals involvement of M-2-muscarinic receptors in control of the kinetics of acetylcholine release. J Neurophysiol 89 (2003) 1954-1967
53. Hemrick-Luecke S.K., Bymaster F.P., Evans D.C., Wess J., and Felder C.C. Muscarinic agonist-mediated increases in serum corticosterone levels are abolished in M-2 muscarinic acetylcholine receptor knockout mice. J Pharmacol Exp Ther 303 (2002) 99-103
54. Tzavaral E.T., Bymaster F.P., Felder C.C., Wade M., Gomeza J., Wess J., et al. Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry 8 (2003) 673-679
55. Cuadra G., Summers K., and Giacobini E. Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo. J Pharmacol Exp Ther 270 (1994) 277-284